Best Kidney cancer oncologists in Turkey: TOP 48 doctors

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Urologist, Oncosurgeon

Licensed Radiation Oncologist with 8 years of medical training, including undergraduate studies at Marmara University Faculty of Medicine (2004-2011) and Radiation Oncology specialization training at Marmara University Faculty of Medicine (2012-2016). Previous education from Sixteen Numbered Shirvan School (Azerbaijan) High School (1998-2004).

Field of Speciality: Urology
Date of Birth: 1980
School of Medicine:  Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English

Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.

Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
mesenchymal Cellular
Male-Shot

​

After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments

His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement   Penile Implants , Penile Enhancement , SafeFill and MaleShot  into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.

(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)

​

Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.

​

​

OTHER AREAS OF FOCUS

Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male in, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias

​

Membership of Scientific Organizations

Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Cells Applications

• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en

​

orchiopexy in cryptorchidism: a single centre experience with long-term follow-up. PEDIATRIC SURGERY INTERNATIONAL, 18 : 140-141, 2002

Uygur MC, Tan MO, Ünal D, Erol D: The outcome of one-stage repair of proximal hypospadias with wide ventral preputial island flap. PEDIATRIC SURGERY INTERNATIONAL, 18: 139-140, 2002

Dr. Uygur is an international urologist with a Medical Graduate and M.D. Degree from Hacettepe University Medical School, a research fellowship from the Transplantation Laboratory of Helsinki University, and residency in Urology from Hacettepe University Medical School. He has over 300 international and national publications and presentations, with 781 scientific citations to 41 articles. He is a full member of the European Association of Urology, a corresponding member of the American Urological Association, a member of the Society of Urologic Oncology, and a board member of the Turkish Society of Urologic Oncology. He has completed robotic urologic surgery courses at Vanderbilt University Hospital, the Cleveland Clinic, and the USC Norris Comprehensive Cancer Center. He is the Professor of Urology and Chair at the Near East University Medical School, the Chief of Urology at the Anadolu Medical Center in Affiliation with Johns Hopkins Medicine, and the Director of Urooncology and Urologic Robotic Surgery Programmes at the Anadolu Medical Center. He is also a scientific secretary of biannual Ankara Urooncology Courses, and has organized many national or regional Urology and Urooncology meetings.

Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:

Breast Cancer

Prostate Cancer

Lung Cancer

Colorectal Cancer

Stomach Cancer

Ovarian Cancer

Prof. Kıvanç Derya Peker completed his medical education and general surgery specialization at Istanbul University Istanbul Faculty of Medicine (Çapa). After his major specialization, he got his Gastroenterology Surgery Specialization from the Gastroenterology Surgery Clinic of Kartal Koşuyolu Yüksek İhtisas Training and Research Hospital by entering the top 3 in the minor examination.

During his sub-branch assistantship, he received a scholarship from the Turkish Surgery Association and worked at Mayo Clinic (Rochester, USA) Hepatopancreatobiliary Surgery Clinic and Obesity-Metabolic Surgery Clinic. After returning to Turkey, He was one of the founders of the Hepatopancreatobiliary Surgery unit at Bakırköy Dr. Sadi Konuk Training and Research Hospital. Peker provided Hepatopancreatobiliary Surgery training to general surgery residents and gastroenterology surgery residents in this hospital, which is accepted as a training unit by the Turkish HPB Association.

On the other hand; In order to learn , cancer biology, cellular properties of obesity and aging, he did his doctorate and thesis on aging at Istanbul University, Istanbul Faculty of Medicine (Çapa), Department of Medical Biology. Then, he moved to Başakşehir Çam and Sakura City Hospital to establish the Gastroenterology Surgery Clinic.

Especially in his career; He is interested in Pancreatic Diseases and Surgery, Gallbladder and Bile Duct Diseases Surgery, Liver Cancer Surgery, Stomach Cancer Surgery and Obesity-Metabolic Surgery. Peker has carried out many successful operations. He has performed over 400 pancreatic and gastric cancer surgeries, over 200 liver surgeries, many surgeries related to gallbladder and biliary tract diseases, obesity – metabolic surgery and endoscopic treatments, and kidney transplants so far. He is also interested in aging and stem cell treatments.

MEDICAL INTERESTS

• Pancreatic Surgery
• Gallbladder and Tracts Surgery
• Liver Diseases Surgery
• Stomach Diseases and Stomach Cancer Surgery
• Obesity – Metabolic Surgery and Endoscopic Treatments
• Kidney Transplant

Assoc. Dr. Görkem TÜRKKAN started his medical education at Gülhane Military Medical Academy in 2003 and completed it in 2009 at Zonguldak Karaelmas (Bülent Ecevit) University Faculty of Medicine. He completed his residency in the Department of Radiation Oncology at Trakya University Faculty of Medicine and became a radiation oncology specialist in 2016.

After completing his compulsory service, he served as a Doctor Lecturer and Head of Department at Muğla Sıtkı Koçman University Faculty of Medicine, Department of Radiation Oncology from May 2019 to February 2021. During this period, between March and June 2020, he worked as a clinical researcher in the Department of Radiation Oncology at Maastricht University Medical Center–MAASTRO Clinic (Netherlands) on studies related to stereotactic radiotherapy, thoracic radiation therapy-associated lung toxicity, and proton therapy. Between March 2021 and April 2023, he worked at the Radiation Oncology Department of Istinye University Faculty of Medicine and Liv Hospital Ulus Radiation Oncology Clinic, where he received the title of Associate Professor in February 2023. He has been providing services to his patients at Hisar Hospital Intercontinental since May 2023.

Throughout his professional life, he has performed both traditional and advanced radiotherapy practices. Particularly, he is one of the experienced physicians in Turkey in stereotactic radiotherapy and MRI-guided radiotherapy treatments, which are gaining popularity and usage recently. So far, he has successfully completed over 2500 radiotherapy sessions using the MR-Linac device.

Since 2013, he has been a member of the Turkish Radiation Oncology Society (TROD) and since 2015 a member of the European Society for Radiotherapy and Oncology (ESTRO). He has 27 published articles in national and international journals, 31 oral-poster presentations at national and international congresses, and 5 book chapters published by national and international publishers. He has taught undergraduate courses in Period I and Period V at Muğla Sıtkı Koçman University Faculty of Medicine, master’s courses within the ENT Department Specialist training, and Radiation Therapy associate degree courses at Istinye University Health Services Vocational School. He is currently involved in 2 ongoing TÜBİTAK Projects. He is married and has one son.

MEDICAL INTERESTS

• MR-Linac
• Linac
• Stereotactic (Precision) Radiotherapy
• Prostate Cancers
• Breast Cancers
• Lung Cancers
• Rectal Cancers
• Brain and Spinal Cord Cancers
• Head and Neck Cancers
• Volumetric Arc Therapy (VMAT)
• Intensity-Modulated Radiation Therapy (IMRT)
• 
   

Born in 1978, Specialist Dr. Mustafa Solak graduated from Hacettepe University Faculty of Medicine. He completed his residency at Istanbul Şişli Etfal Training and Research Hospital and received his Sub-specialty from Hacettepe University Cancer Institute.

He has numerous cases related to Breast Cancer, Testicular Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancers, and Gastrointestinal System Cancers.

MEDICAL INTERESTS

• Breast Cancer
• Testicular Cancer
• Ovarian Cancer
• Lung Cancer
• Head and Neck Cancers
• Gastrointestinal System Cancers

Areas of Interest
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Skin Cancer
Stomach Cancer
Liver Cancer
Cervical Cancer
Kidney Cancer
Pancreatic Cancer
Esophageal Cancer

Education
2014 – 2017
Hacettepe University Oncology Institute, Department of Medical Oncology

2009 – 2013
Ufuk University Faculty of Medicine, Department of Internal Medicine

1999 – 2006
Eskişehir Osmangazi University Faculty of Medicine

Work Experience
2024
Neolife Medical Center

2024
Kolan Beylikdüzü Hospital

2023 – 2024
Memorial Bahçelievler Hospital

2020 – 2023
Acıbadem Maslak Hospital

2019 – 2020
İstanbul Aydın University VM Medicalpark Florya Hospital

2017 – 2019
Ministry of Health, Van Education and Research Hospital

2014 – 2017
Hacettepe University Oncology Institute, Medical Oncology Department

2013 – 2014
Kars State Hospital

2009 – 2013
Ufuk University, Dr. Rıdvan Ege Hospital, Department of Internal Medicine

2007 – 2009
Hacettepe University Faculty of Medicine, Department of Physiology

Professional Training
Participation in Turkish Medical Oncology Congresses, National Cancer Congresses, National Immunotherapy and Oncology Congresses
Courses of the Turkish Society of Medical Oncology

Memberships
Turkish Society of Medical Oncology
Istanbul Medical Chamber

Scientific Publications
6 scientific publications in national and international journals
21 abstracts presented at national congresses
3 abstracts presented at international congresses
1 book chapter translation: Atlas of Internal Medicine, 3rd Edition, Chapter 12 – Hepatology, Turkish Translation
3 book chapters:

1. Immunotherapy in Oncology. Immunotherapy in Small Cell Lung Cancer, Chapter 13, 2020
2. Endocrine System Tumors. The Role of Immunotherapy in Neuroendocrine Tumors, Chapter 41, 2021
3. Antineoplastic Drugs. Mechanisms of Action and Classification of Antimetabolites, Chapter 14, 2022
   1 oral presentation at a national congress: Chemotherapy in Cervical Cancer – 3rd National Urogenital Cancer Congress, 2019
   3 abstracts presented at international congresses

Education

2000
Medical School Graduate – Istanbul University, Faculty of Medicine

2005
Radiology Department, Istanbul University, Istanbul Medical Faculty

Work Experience

2022 – Present
Neolife Medical Center

2015 – 2021
Sonomed Imaging Center

2015
Bezmialem Vakıf University

2011 – 2015
Echomar Imaging Center

2010 – 2011
Istanbul Bilim University

2008 – 2009
Derince Military Hospital

2007 – 2008
German Hospital-Taksim

2005 – 2007
Echomar Imaging Center

Professional Trainings

• National Radiology Congresses
• National Magnetic Resonance Society Meetings

Memberships

• Turkish Radiology Society
• Turkish Magnetic Resonance Society
• Turkish Neuroradiology Society
• RSNA (Radiological Society of North America)
• ESR (European Society of Radiology)

Scientific Works

MRI findings in parosteal osteosarcoma: correlation with histopathology.
Dönmez FY, Tüzün U, Başaran C, Tunaci M, Bilgiç B, Acunaş G. Diagn Interv Radiol. 

The diagnostic efficiency of multislice CT virtual bronchoscopy in detecting endobronchial tumors.
Bakir B, Tüzün Ü, Terzibaşioğlu E, Dursun M, Güven K, Salmaslioğlu A, Tunaci A. Tuberk Toraks.

Diffusion MR findings in cyclosporin-A induced encephalopathy.
Aydin K, Donmez F, Tuzun U, Minareci O, Atamer T. Neuroradiology. 2004 

Diffusion tensor imaging findings of the brainstem in subjects with tonsillar ectopia.
Kurtcan S, Alkan A, Yetis H, Tuzun U, Aralasmak A, Toprak H, Ozdemir H. Acta Neurol Belg. 2018 Mar;

Diffusion Tensor Imaging Parameters in Children with Acute Hyperammonemic Encephalopathy Due to Urea Cycle Enzyme Defects and Organic Acidemia.
Kurtcan S, Alkan A, Guler S, Yesil G, Toprak H, Tuzun U, Yetis H, Aralasmak A, Ozdemir H, Iscan A. Current Medical Imaging Reviews. Volume 13, 2017 DOI: 10.2174/

The Contribution of DTI in Determining the Relationship of Epilepsy and Brain Lesions in Children with Tuberous Sclerosis.
Kurtcan S, Alkan A, Guler S, Yesil G, Toprak H, Tuzun U, Yetis H, Aralasmak A, Ozdemir H, Iscan A. Current Medical Imaging Reviews. Volume 13, 2017 DOI: 10.2174/

Brainstem cranial nerve diffusion changes in Wernicke encephalopathy secondary to necrotizing pancreatitis.
Kurtcan S, Alkan A, Aydin S, Tuzun U, Toprak H. Arch Med Sci Civil Dis 2016;1:e45–e50

Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies.
Ediz S.S, Kurtcan S, Alkan A, Aydin S, Tuzun U, Toprak H, Aralasmak A. Current Medical Imaging Reviews. Volume 13, 2017

Does the Application of Platelet-Rich Fibrin in Anterior Cruciate Ligament Reconstruction Enhance Graft Healing and Maturation? A Comparative MRI Study of 44 Cases.
Beyzadeoglu T, Pehlivanoglu T, Yildirim K, Buldu H, Tandogan R, Tuzun U. Orthop J Sports Med. 2020 Feb 20;8(2):

Deep learning for assessing image quality in bi-parametric prostate MRI: A feasibility study.
Alis D, Kartal MS, Seker ME, Guroz B, Basar Y, Arslan A, Sirolu S, Kurtcan S, Denizoglu N, Tuzun U, Yildirim D, Oksuz I, Karaarslan E. Eur J Radiol. 2023 Aug;165:110924. doi: 10.1016/j.ejrad.2023.110924. Epub 2023 Jun 11.

Awards

1. TMRD 16th Annual Meeting Film Reading Session - 2nd Prize (2011)
2. TMRD 17th Annual Meeting Film Reading Session - 3rd Prize (2012)
3. TMRD 17th Annual Meeting Case of the Day - 3rd Prize (2012)
4. TRD 33rd National Congress Case of the Day - 2nd Prize (2012)
5. TMRD 18th Annual Meeting Film Reading Session - 3rd Prize (2013)
6. TMRD 18th Annual Meeting Case of the Day - 3rd Prize (2013)
7. TMRD 19th Annual Meeting Film Reading Session - 2nd Prize (2014)
8. TMRD 19th Annual Meeting Case of the Day - 1st Prize (2014)
9. TRD 36th National Congress Case of the Day - 2nd Prize (2015)
10. TMRD 21st Annual Meeting Film Reading Session - 1st Prize (2016)
11. TRD 37th National Congress Case of the Day - 1st Prize (2016)
12. TMRD 37th National Congress Film Reading Session - 1st Prize (2016)
13. TMRD 23rd Annual Meeting Film Reading Session - 1st Prize (2018)